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ABSTRACT
Background: Grade 3 and 4 adverse events (AEs) during cycle 1 are traditionally 
used for dose escalation decisions in Phase I oncology trials. With molecularly 
targeted agents (MTAs), assessment of lower grade AEs and those in later cycles is 
considered increasingly relevant.
Methods: We conducted a retrospective analysis of AEs in patients enrolled onto 
relevant phase I trials of MTAs and cytotoxic combinations (CCs) at our UK centre 
between 2006 and 2016. All AEs in the first six cycles deemed at least ‘possibly 
related’ were recorded.
Results: A total of 912 AEs were identified in 127 patients across 15 trials. Mean 
AE totals for CCs or MTAs respectively was 4.7 versus 3.0 in cycle 1, 3.8 versus 2.8 
in cycles 2-6. Patients on CCs had higher mean AEs in six cycles compared to those 
on MTAs (8.5 vs. 5.7, p = 0.0005). For patients experiencing grade 3 AEs, 58% (CCs) 
and 60% (MTAs) occurred for the first time after cycle 1.
Conclusion: Overall AE incidence was lower in MTAs than CCs across six cycles. 
For MTAs, more frequent incidence of first grade 3/4 AEs after cycle 1 supports 
incorporation of delayed AEs into recommendations for Phase 2 dosing.
INTRODUCTION
Adverse events (AEs) in early phase oncology trials 
play a key role in dose escalation [1], with dose-limiting 
toxicities (DLTs) being particularly important. While AEs 
and DLTs are recorded throughout the entirety of a trial, 
occurrences beyond the DLT window (cycle 1) are rarely 
incorporated into subsequent publication [2].
It has been established that there is variation in DLTs 
between cytotoxic and non-cytotoxic agents [3]. Cytotoxic 
agents generally exhibit more severe and higher grades of 
toxicity in earlier cycles [4], whereas molecularly targeted 
agents (MTAs) are often administered chronically until 
progression, making consideration of lower grade AEs 
and those in later cycles highly relevant [2, 5, 6]. This 
has led to investigators having to consider how to address 
both late and dose-limiting toxicities across drug types 
[7]. Some investigators have suggested the classic DLT 
window should be extended to take into account MTAs 
toxicity [2, 8]. However, differences in the timing and 
severity of cytotoxic and MTAs AEs suggest a need for 
flexibility in managing different trial types [9].
To our knowledge, there has been no previous 
investigation into differences in AEs in phase I trials 
of MTAs compare to cytotoxic combinations (CCs) 
over time. The primary objective of this study was to 
analyse AEs from patients enrolled on relevant phase I 
dose escalation trials at a single UK centre to determine 
incidence of AEs between drug classes (CCs versus 
MTAs), and between cycle 1 versus cycles 2-6.
Previous work has compared single agent cytotoxic 
and MTA dermatological AEs and found a substantial 
number of AEs occurring outside the DLT window with 
variation in AE type based on agent studied [10]. It has 
been suggested that toxicities from all cycles should be 
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taken into account for analysis and reporting of phase I 
trials [11].
In line with previous work suggesting ethnic, age 
and gender based risk of toxicities [12], the secondary 
objective of this study was to determine differences in 
incidence of AEs across specific clinical, demographic and 
socio-economic cohorts.
RESULTS
Patient demographics
A total of 127 patients’ records were accessed; of 
these, 67 patients were enrolled onto CCs and 60 patients 
were enrolled onto MTAs trials (Figure 1). Patients on 
CCs completed a total of 241 cycles and patients on MTAs 
completed a total of 179 cycles. Average cycles completed 
was 4.0 in CCs and 3.0 in MTAs. Of 127 patients, 52 
(40.9%) were men and 75 (59.0%) were women, with 
a mean average age at trial start of 59 years (61.1 years 
for men and 57.6 years for women). Table 1 shows other 
baseline characteristics relevant to this study.
Trial characteristics and cycles completed
Patients were enrolled on a total of 15 trials (7 
CCs and 8 MTAs). Details of specific MTAs pathways 
and cytotoxic drug mechanisms of action can be found in 
Table 2.
Of 67 patients who begun a CC trial, all completed 
cycle 1, 67 (83.6%) progressed to cycle 2, 39 (58.2%) 
progressed to cycle 3, 32 (47.8%) to cycle 4, 26 (38.8%) 
to cycle 5 and 21 (31.3%) completed all six cycles.
In the MTAs trials, all 60 patients completed cycle 
1 successfully, with 52 (86.6%) progressing to cycle 2, 27 
(45.0%) reaching cycle 3, 21 (35.0%) completed cycle 4, 
11 (18.3%) in cycle 5 and a total of eight (13.3%) patients 
completed all six cycles.
Figure 1: CONSORT flow diagram. Flow of patients selected for analysis in this study.
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Table 1: Patient demographics
 N (%)
Age  
 25-34 4 (3.15)
 35-44 14 (11.02)
 45-54 21 (16.54)
 55-64 46 (36.22)
 65-74 30 (23.62)
 75-84 12 (9.45)
Gender  
 Male 52 (40.94)
 Female 75 (59.06)
Ethnicity  
 Caucasian 91 (71.65)
 Not Caucasian 15 (11.81)
 Not Specified 21 (16.54)
Charlson Comorbidity Index Score  
 0 85 (66.93)
 1 21 (16.54)
  ≥2 3 (2.36)
 Unknown 18 (14.17)
Index of Multiple Deprivation Score  
 1 (least deprived) 22 (17.32)
 2 22 (17.32)
 3 21 (16.54)
 4 36 (28.35)
 5 (most deprived) 21 (16.54)
 Not Stateda 5 (3.93)
Number of Metastatic Sites  
 0 1 (0.79)
 1 39 (30.71)
 2 46 (36.22)
 3 23 (18.11)
 4 5 (3.94)
 5 1 (0.79)
 Unknown 12 (9.44)
Previous Radiotherapy  
 Yes 39 (30.71)
 No 70 (55.12)
 Unknown 18 (14.17)
(Continued )
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 N (%)
Previous Lines of Chemotherapy  
 1 39 (30.71)
 2 30 (23.62)
 3 18 (14.17)
 4 12 (9.45)
  ≥5 11 (8.66)
 Unknown 17 (13.39)
Neutrophil-Lymphocyte Ratio  
 <5 75 (59.06)
  ≥5 33 (25.98)
 Unknown 19 (14.96)
Royal Marsden Hospital Score  
 Low 90 (70.87)
 High 19 (14.96)
 Unknown 18 (14.17)
Demographics of the 127 patients referred to the early phase trials unit at Guy’s Hospital London who subsequently went 
on a dose escalation trial and had their adverse events recorded for this study.
a – includes patients who did not have an English postcode.
Table 2: Trial characteristics
 Patients (%)/ Trials
Cytotoxic Combination Trials (N=7)  
Cytotoxic Agents  
 Platinum + Taxane 28 (41.8) / 1
 Cyclophosphamide 19 (28.4) / 3
 Taxane 20 (33.3) / 3
Molecularly Targeted Agent Trials (N=8)  
MTA Pathways  
 HER Inhibitor 27 (45.0) / 2
 Notch Inhibitor 4 (6.7) / 1
 ATR Inhibitor 2 (3.3) / 1
 PI3 Kinase Inhibitor 3 (5.0) / 1
 PARP Inhibitor 13 (21.6) / 1
 CYP17A1 Inhibitor 9 (15.0) / 1
 FGFR4 Inhibitor 2 (3.3) / 1
Characteristics of trials in which the 127 patients analysed in this study were enrolled onto and participated in, with specific 
divisions the type of cytotoxic agent used and the pathways of the molecularly targeted agents.
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Failure to complete six cycles of treatment was due 
to either progressive disease or toxicity.
Adverse events
A total of 912 AEs recorded in 127 patients. By 
trial, 568 AEs were recorded from the 67 patients on 
CCs, 316 (56.6%) of these occurred during cycle 1, while 
252 (44.4%) occurred within cycles 2-6. A total of 344 
AEs were recorded in 60 patients on MTAs, 177 (51.5%) 
occurred within cycle 1 and 167 (48.5%) in cycles 2-6.
The highest AE total in an individual patient on CCs 
was 20 (range 0-20), 16 for a patient on MTAs (range 
0-16). Mean average AE total per patient on CCs for cycle 
1 and cycles 2-6 were 4.7 and 3.8 respectively, while 
average AE total per patient on MTAs trials in cycle 1 was 
3.0, with a 2.8 average in cycles 2-6.
Average AE totals for six cycles were 8.5 and 5.7 for 
patients on CCs and MTAs trials respectively (p = 0.0005), 
indicating that patients on CCs experienced a significantly 
larger number of AEs in six cycles compared with those 
on MTAs trials.
Figure 2A shows AEs split by trial type, either CCs 
or MTAs. AEs recorded were split by CTCAE grade with 
grades 1 and 2 being most prevalent in both groups. AEs 
were then split by cycle number (Figure 2B) and arranged 
by trial type, either CCs or MTAs. AEs in cycles 1 and 2 
Figure 2: Adverse events by trial type. Adverse events collected from patients of each trial type, cytotoxic combination and MTAs 
single agent, split by (A) CTCAE grade 1-6 and (B) cycle number 1-6.
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accounted for the majority with AEs occurring throughout 
all cycles in both groups.
Table 3 shows AEs ranked by incidence in cycle 
1 and cycles 2-6. Fatigue and diarrhoea showed high 
incidence in all cycles. Beyond cycle 1, AEs such as 
anorexia and vomiting became more apparent in all 
patients.
Time to first adverse event
Cumulative AE incidence by grade was evaluated 
by the creation of time to first AE curves. For CCs (Figure 
3A), of the 24 patients who experienced G3 toxicity, 58% 
presented for the first time after cycle 1. Incidence of G4 
toxicity beyond cycle 1 was of a similar occurrence, with 
43.0% of patients with G4 toxicity presenting for the first 
time in cycles 2-6.
In MTAs trials (Figure 3B), 34.0% of patients 
who experienced G2 toxicity presented following cycle 
1 (taking into account decreasing number of patients per 
cycle); there was a gradual increase of first incidence G2 
toxicity throughout all six cycles. G3 toxicity incidence 
was low overall (5 patients) but three events occurred 
for the first time beyond cycle 1. Log-rank (Mantel-
Cox) tests were performed to compare incidence of 
each grade between trial types; G1, G2 and G5 all 
showed no significant difference (p-values > 0.05). G3 
showed a highly significant difference (p-value 0.0033) 
between CCs and MTAs trials; G4 toxicity also showed 
a significant difference between CCs and MTAs (p-value 
0.01).
Adverse events across clinical, demographic and 
socioeconomic variables
Statistical analyses were performed across a range 
of clinical, demographic and socioeconomic variables 
(Table 1) comparing mean AE values in cycle 1, cycles 
2-6 and overall. There were no statistically significant 
differences (p-values > 0.05) in AEs across age, gender, 
ethnicity, comorbidity index, depravation index, number 
of metastatic sites, prior radiotherapy or chemotherapy, 
NLR and RMH scores.
Treatment interruptions and dose modifications
Events that were directly caused by toxicity, 
resulting in dose interruptions, dose reductions or a 
removal of a patient from the trial they were enrolled in, 
were recorded. These interruptions and modifications 
consisted of 52 AEs, resulting in 37 events in a total of 
28 patients. AEs involved in these events were split by 
grade; G1 = 5, G2 = 26, G3 = 20, G4 = 1 and G5 = 0. 
These AEs spanned nine different categories (Figure 4B), 
with constitutional and dermatological events accounting 
for the majority (57.7%).
Figure 4A shows events split by trial type. Of 37 
events, 41.0% occurred in patients on CCs and 59.0% in 
Table 3: Top 10 adverse events
Cytotoxic Combination Trials (N=67) Molecularly Targeted Single Agent Trials (N=60)
Cycle 1 n (%) Cycles 2-6 n (%) Cycle 1 n (%) Cycles 2-6 n (%)
Diarrhoea 36 (53.7) Fatigue 24 (35.8) Fatigue 25 (41.7) Fatigue 20 (33.3)
Rasha 32 (47.8) Diarrhoea 19 (28.4) Diarrhoea 19 (31.7) Anorexia 12 (20.0)
Fatigue 28 (41.8) Mucositisb 18 (26.9) Nausea 18 (30.0) Diarrhoea 10 (16.7)
Mucositisb 23 (34.3) Alopecia 14 (20.9) Rasha 14 (23.3) Rasha 9 (15.0)
Nausea 22 (32.8) Rasha 12 (17.9) Mucositisb 9 (15.0) Vomiting 9 (15.0)
Pyrexia 16 (23.9) Vomiting 12 (17.9) Anorexia 8 (13.3) Nausea 9 (15.0)
Anorexia 11 (16.4) Nausea 10 (14.9) Dysgeusia 6 (10.0) Oedema 6 (10.0)
Constipation 9 (13.4) Anorexia 10 (14.9) Urine Discoloration 5 (8.3)
Increased 
Bilirubin 5 (8.3)
Epistaxis 8 (11.9) Anaemia 9 (13.4) Dry Skin 5 (8.3) Mucositisb 5 (8.3)
Neutropeniac 8 (11.9) Neutropeniac 8 (11.9) Dyspepsia 5 (8.3) Pain 5 (8.3)
Ranked adverse events by trial type and cycle number, either cycle 1 or cycles 2-6. AEs were ranked to show top 10 in each 
trial and cycle group. AEs are displayed in ascending order of raw count with percentage incidence given in brackets.
a including pruritic, fungal, macropapular, acneiform, pustular.
b including stomatitis and coryzal symptoms.
c including resultant fever or sepsis.
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patients on MTAs trials. Events were spread throughout 
cycle 1, 2 and 3 in patients on CCs whereas events were 
also recorded in cycle 5 for patients in MTAs trials. The 
majority of events in patients on CCs occurred within 
cycle 1 (60.0%) however the majority of events in those 
on MTAs occurred beyond cycle 1, with a total of 13 
events (59.0%) in cycles 2-5 (p > 0.05).
Figure 4C shows the distribution of event types by 
trial (dose interruptions, dose reductions and off trial). 
Patients on CCs experienced a higher incidence of dose 
interruptions (46.6% versus 27.3% for patients on MTAs). 
Dose reductions were the highest in patients on MTAs 
trials, accounting for 54.5% (12/22 events), and 33.3% 
(5/15) of events in CCs. Number of AEs contributing to 
each event is shown in Figure 4D. Highest AE total in one 
event was six and was recorded in a patient on a MTAs 
trial.
Dose limiting toxicities
Of 37 events causing treatment interruptions or dose 
modifications, 17 were classified as DLTs, 10 occurring 
within the DLT window (cycle 1) and 7 in cycles 2-6.
Split by trial type, 50% of traditional DLTs occurred 
on CCs and 50% occurred in those on MTAs trials. Of 
the DLT events beyond cycle 1, 43.0% were recorded in 
patients on CCs and the remaining 57.0% in patients on 
MTAs trials. Irrespective of cycle, DLT events in patients 
on CCs accounted for 1.4% of all AEs, whereas for patients 
on MTAs trials DLT events made up 2.6% of all AEs.
Figure 3: Time to first adverse event. Cumulative incidence (in percentage) of patients experiencing their first adverse event of each 
grade (1-5) in cycles 1 to 6 of (A) cytotoxic combination trials and (B) molecularly targeted agent trials. Taking into account patients who 
have already experienced adverse events of each grade and patients who were no longer on treatment at each cycle.
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DISCUSSION
Evaluation of the differences of adverse events in 
cytotoxic and molecularly targeted agents is a prominent 
consideration in early phase trials. Cytotoxic AEs typically 
occur more acutely and show higher incidence of increased 
severity [4], whereas MTAs AEs present more chronically 
with a lower level of toxicity [13].
Previous studies have evaluated specific aspects of 
toxicity patterns in phase I trials, such as the emergence of 
MTAs AEs [14] and variation in DLT events [3]. With that 
in mind, this study set out to investigate a broader toxicity 
perspective by including all AEs recorded.
To our knowledge, this is the first study to assess 
differences in incidence of AEs between MTAs and 
CCs, and across different cycle numbers. A total of 912 
AEs were recorded across 420 cycles of treatment in 
127 patients. We have confirmed that patients on CC 
trials experienced a significantly higher number of AEs 
over six cycles compared with MTAs. This is in keeping 
with previous data from other series, supporting findings 
that patients on CCs experience a higher volume of AEs 
[15] than MTAs [16]. These findings were supported by 
a significantly higher cumulative incidence of patients 
on CC trials experiencing their first G3 and G4 toxicity 
over six cycles. Incidence of first G2 and G3 toxicities 
in patients on MTAs trials increased steadily throughout 
cycles 2-6, highlighting the later presentation of toxicities 
with MTAs [2].
Treatment interruptions and dose modifications 
showed no significant difference between trial types or 
cycles, however the numbers of patients in these subgroups 
were too small to draw meaningful comparisons. 
Nevertheless there was still a notable amount of these 
events following the completion of cycle 1 in both trial 
types, an important finding given that dose interruptions 
and reductions can lead to suboptimal therapeutic 
outcomes [17]. DLT comparisons between both trial types 
(CCs versus MTAs) and cycles (cycle 1 versus cycles 2-6) 
support previous work, indicating that the DLT period 
is not long enough and should be extended beyond the 
traditional DLT window of cycle 1 [8].
The main limitation of this study is the lack of 
prospective recording of asymptomatic haematological 
and biochemical abnormalities. Although this is unlikely 
to interfere with the conclusions reached, in the future 
these laboratory results should be prospectively CTCAE 
graded and included for a broader evaluation of all AEs. 
In addition, the retrospectively analysis of AEs is another 
limitation of this study; prospective analysis of both 
symptomatic and laboratory AEs would allow for more 
accurate information to be recorded for each patient.
Age and ethnicity have been suggested to 
influence toxicity [12] in a large variety of drugs not 
Figure 4: Treatment interruptions and dose modifications. Display of several variables relating to treatment interruptions and 
dose modifications. Events included dose interruptions, dose reductions or removal of patient from trial. Results displayed as; (A) events 
by trial type – cytotoxic combination or molecularly targeted single agent; (B) AEs contributing to all events split by category; (C) events 
by type – dose interruption, dose reduction (*including dose interruptions that resulted in dose reductions) and removal of patient from trial; 
(D) events by number of contributing AEs.
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just chemotherapeutic agents [18–20]. In addition, 
number of metastatic sites, NLR and RMH scores are 
important indicators of prognosis [21]. These variables 
were therefore analysed for differences in toxicity. 
Gender, comorbidity index score, socioeconomic status, 
radiotherapy history and chemotherapy history were also 
evaluated. In the cohorts studied, there was no significant 
difference found between any subgroup of the variables 
tested, potentially due to small sample size. Although 
these results are comparatively different to some previous 
studies [12], this lack of significant difference in toxicity 
may be beneficial with regards to enrolment of patients 
on phase 1 trials. Previous work from our centre has 
demonstrated that patients from a lower socioeconomic 
background (based on index of multiple depravation) are 
statistically less likely to be referred to a trials unit [22].
The results of this study provide an evaluation 
of drug toxicities between patients treated in cytotoxic 
combination and MTA trials. The data presented here, 
showing more frequent incidence of first grade 3-4 AEs 
after cycle 1 for MTAs, supports the routine incorporation 
of delayed AEs into recommendations of Phase 2 dosing 
and schedule for these agents.
MATERIALS AND METHODS
Patients and trial characteristics
Patients enrolled on phase I dose escalation trials 
in the early phase oncology trials unit at Guy’s Hospital, 
London, United Kingdom between March 2006 and May 
2016 were selected. For patients enrolled onto multiple 
trials, only the first trial was included for data collection.
127 patients were identified as those who were 
enrolled onto phase I dose escalation trials, completed 
at least one cycle of treatment and had accessible source 
data for recording (Figure 1). Seventy patients were 
entered onto a total of seven combination trials containing 
cytotoxic agents and 60 patients were entered onto a total 
of eight single agent trials involving MTAs.
All patients were anonymised to maintain 
confidentiality.
Data collection
All data was collected on a retrospective basis using 
computer sources including the electronic patient record 
system (EPR) alongside the oncology and haematology 
clinical information system (CIS). Paper sources of data 
included source data files from the local and external 
Guy’s and St Thomas’ NHS Foundation Trust (GSTT) 
trial archives.
Adverse events
All AEs that were deemed at least ‘possibly related’ 
and were not classified as present at baseline were 
recorded throughout cycles 1 to 6. All AEs were graded 
using the Cancer Institute Common Terminology Criteria 
of Adverse Events (CTCAE), version 3.0 (4 trials) or 
version 4.3 (11 trials).
Other variables
Information regarding patient variables such as 
comorbidity index, neutrophil-lymphocyte ratio (NLR), 
Royal Marsden Hospital (RMH) score and socioeconomic 
status was collected. Socioeconomic status was assessed 
using the Index of Multiple Depravation (IMD) tool, 
provided online by the University of Oxford National 
Perinatal Epidemiology Unit (NPEU), which calculates 
IMD based on English postcodes.
Data analysis
Raw AE data was organised and manipulated to 
provide total AE values per patient to a total of up to six 
cycles. Total number of cycles completed was recorded for 
each patient and total AEs per cycle calculated.
All results were transferred to the statistical analysis 
software GraphPad Prism 7 (GraphPad Software, Inc.; 
California, USA), where data was organised to calculate 
specific results and statistical analyses were performed 
where necessary. Multiple unpaired two-tailed t-tests 
and one-way ANOVA tests were performed to identify 
any significant difference in AE incidence within the 
subgroups of the following variables; age, gender, 
ethnicity, comorbidity index, depravation index, number 
of metastatic sites, radiotherapy history, chemotherapy 
history, NLR and RMH scores.
Analysis of time to first AE data was performed 
using log-rank (Mantel-Cox) tests alongside a log-rank 
test for trend. For analysis of treatment interruption and 
dose modification events between trial types, two-way 
ANOVA and further t-tests were performed.
For all results, a p-value of ≤0.05 was deemed to be 
significant.
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